

## Appendix A - Immune Compromise Category – Evushed administration (prepared by MDJ)

### 1) Category 1 (highest risk)

- a. Lung transplant recipient (any time frame).
- b. Small bowel transplant recipient (any time frame).
- c. Receipt of the following immunosuppressive medication within the past 12 months (including for solid organ transplant).
  - i. Anti-thymocyte globulin (ATG)
  - ii. Alemtuzumab
  - iii. Anti-B-cell therapy (e.g., rituximab, ocrelizumab, ofatumumab)
- d. B-cell malignancies, on active treatment (e.g., B-cell lymphomas, chronic lymphocytic leukemia, acute B-cell lymphoblastic leukemia, etc.).
- e. Multiple myeloma, on active treatment with two or more agents.
- f. Allogeneic stem cell transplant, within 12 months of transplant.
- g. Autologous stem cell transplant, within six months of transplant.
- h. Receipt of anti-CD19 or anti-BCMA (CAR)-T-cell immunotherapy, within six months of treatment.
- i. Primary or secondary T-cell immunodeficiency, including severe combined immunodeficiency.
- j. Recipient of more than one active transplant, different organs (any time frame), e.g., kidney-pancreas, heart-kidney
- k. Acute myeloid leukemia under active treatment.

### 2) Category 2

- a. Any solid organ transplant within the past 12 months from date of transplant, not otherwise eligible in Category 1.
- b. Allogeneic stem cell transplant, more than 12 months since transplant.
- c. Autologous stem cell transplant, more than 6 months since transplant.

### 3) Category 3

- a. Any solid organ transplant recipient more than 12 months since transplant AND aged 70 or older.
- b. Any solid tumor, on active myelosuppressive chemotherapy.
- c. Multiple myeloma, on maintenance therapy.

### 4) Category 4

- a. Active treatment with high-dose corticosteroids (i.e., more than 20 mg prednisone or equivalent per day when administered for two weeks or longer).
- b. **Active** treatment with other biologic agents that are immunosuppressive or immunomodulatory, not otherwise listed in Categories 1-3. This can include mycophenolate, azathioprine, 6-MP, methotrexate, although I consider these lower risk. This doesn't include HCQ or anti-TNF inhibitor monotherapy.
- c. Any solid organ transplant recipient more than 12 months since transplant, not otherwise eligible in Categories 1-3.
- d. Advanced or untreated HIV infection.
- e. HIV with CD4 less than 200/mm<sup>3</sup> (if aged less than 14 years, CD4% less than 15%)
- f. AIDS-defining illness